Skip to NavigationSkip to content

Roche's Tecentriq combo extends life in untreated lung cancer

Published on 25/06/18 at 10:17am

Roche has unveiled new data on the efficacy of Tecentriq (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the treatment of previously untreated extensive-stage small cell lung cancer (ES-SCLC), revealing that the combo met its co-primary endpoints and was proven to significantly extend life for compared to chemotherapy alone.

The study marked the fourth positive Phase 3 lung cancer study for Tecentriq this year, and the fifth positive study overall. The findings of the study also showed that the combination, when used as a first-line treatment, improved progression-free survival (PFS) versus chemotherapy alone, while its safety profile proved to be consistent with the known profiles of the individual medicines involved. Roche said the new data would be presented at an upcoming medical meeting.

“These are the first positive Phase III survival results for any immunotherapy-based combination in the initial treatment of extensive-stage small cell lung cancer, a particularly difficult-to-treat type of disease,” commented Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “The clinically meaningful results from the IMpower133 study add to the growing body of evidence demonstrating that Tecentriq-based combinations may be an effective treatment for different types of advanced lung cancer. We look forward to working with health authorities globally to bring this potential treatment option to people with this type of disease as soon as possible.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches